Zenas Biopharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Key Stats

• Today's Range: $9.60 to $10.49
• 50-Day Range: N/A
• 52-Week Range: $5.83 to $26.25
• Volume: 79,751 shs
• Average Volume: 194,838 shs
• Market Capitalization: $418.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.00
• Consensus Rating: Buy

ZBIO Stock Analysis - Frequently Asked Questions

How have ZBIO shares performed this year?

Zenas Biopharma's stock was trading at $7.90 at the start of the year. Since then, ZBIO shares have increased by 26.8% and is now trading at $10.02.
View the best growth stocks for 2025 here.

When did Zenas Biopharma IPO?

Zenas Biopharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

When did the company's lock-up period expire?

Zenas Biopharma's lock-up period expired on Wednesday, March 12th. Zenas Biopharma had issued 13,235,294 shares in its IPO on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Zenas Biopharma's major shareholders?

Zenas Biopharma's top institutional investors include Rhumbline Advisers (0.03%).

How do I buy shares of Zenas Biopharma?

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zenas Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: N/A
• Phone: (857) 271-2954
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $40.00
• High Stock Price Target: $45.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +299.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 83.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,799,000
• Free Float: N/A
• Market Cap: $418.83 million
• Optionable: N/A
• Beta: N/A